Imunon, Inc. Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, before Tax (Deprecated 2013-01-31)
Imunon, Inc. (IMNN) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, before Tax (Deprecated 2013-01-31) of $53.74 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-09.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax · last filed 2013-05-09
- Imunon, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, before tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $53.74K, a 58.20% decline year-over-year.
- Imunon, Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, before tax (deprecated 2013-01-31) for the quarter ending 2012-03-31 was $128.56K.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, before Tax (Deprecated 2013-01-31) 1 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, before Tax (Deprecated 2013-01-31) 3 month |
|---|---|---|
| 2013-03-31 | $53.74K 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $108.00K 10-K · filed 2013-03-18 | |
| 2012-03-31 | $128.56K 10-Q · filed 2013-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |